Seeking Alpha

More on Watson Pharma (WPI +2.1%) Q1: Net income +21% to $54.8M, with earnings boosted by...

More on Watson Pharma (WPI +2.1%) Q1: Net income +21% to $54.8M, with earnings boosted by Watson's generic versions of the Lipitor cholesterol drug and Lovenox blood thinner, and a rise in international sales. 2012 guidance: adjusted EPS $5.55-$5.80 and revenue $5.5B vs. consensus of $5.80 and $5.5B.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector